Vice Chancellor Leo Strine indicated he wants further details on Oracle's revised takeover offer and, particularly, why PeopleSoft's board rejected its competitor's unconditional $24-a-share offer, according to reports in the Associated Press and Dow Jones.
Strine called for a new hearing on Dec. 13 and Dec. 14 to review the matter and take in new evidence, as well as to consider Oracle's request to prevent the application of PeopleSoft's shareholder rights plan, otherwise known as a poison pill.
Oracle and PeopleSoft previously argued their positions in October during a two-week trial in the Delaware Chancery Court. At the conclusion of the trial, which largely focused on the previous considerations the companies gave to the merger and PeopleSoft's customer assurance guarantee program, Strine said he would meet with the parties in late November to further discuss whether more hearing dates would be necessary to review PeopleSoft's poison pill.
The Delaware Chancery Court, historically, has been reluctant to remove a company's poison pill, which floods the market with additional shares and makes a hostile takeover cost-prohibitive.
SponsoredWhite Papers, Webcasts, and Downloads
- Building the Virtualized Enterprise with VMware Iinfrastructure VMware VMware virtualization software has been adopted by over 120,000 enterprise ... Download Now
- The Impact of Virtualization Software on Operating Environments VMware Today's use of virtualization technology allows IT professionals to ... Download Now
- Reducing Server Total Cost of Ownership with VMware Virtualization Software VMware VMware virtualization enables customers to reduce their server TCO and ... Download Now
- Talkback
- Most Recent of 3 Talkback(s)
- Thread View
- Flat View
- I agree and the PS shareholders see it too.
- I suspect that was why they voted to accept the offer... (Read the rest)
- Posted by: No_Ax_to_Grind Posted on: 11/24/04 You are currently: a Guest | Log in | Terms of Use
|
|
|
|
|
|


